CU20120080A7 - Formulaciones de anticuerpo - Google Patents
Formulaciones de anticuerpoInfo
- Publication number
- CU20120080A7 CU20120080A7 CU2012000080A CU20120080A CU20120080A7 CU 20120080 A7 CU20120080 A7 CU 20120080A7 CU 2012000080 A CU2012000080 A CU 2012000080A CU 20120080 A CU20120080 A CU 20120080A CU 20120080 A7 CU20120080 A7 CU 20120080A7
- Authority
- CU
- Cuba
- Prior art keywords
- antibody formulations
- formulations
- cryoprotectants
- cryoprotectant
- buffer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002577 cryoprotective agent Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2859CH2009 | 2009-11-20 | ||
| PCT/IB2010/055296 WO2011061712A1 (en) | 2009-11-20 | 2010-11-19 | Formulations of antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20120080A7 true CU20120080A7 (es) | 2012-10-15 |
Family
ID=44059267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2012000080A CU20120080A7 (es) | 2009-11-20 | 2012-05-21 | Formulaciones de anticuerpo |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20120231009A1 (OSRAM) |
| EP (2) | EP3721904B1 (OSRAM) |
| JP (2) | JP5896471B2 (OSRAM) |
| KR (1) | KR101333276B1 (OSRAM) |
| CN (1) | CN102770157B (OSRAM) |
| AU (1) | AU2010320515B2 (OSRAM) |
| BR (1) | BR112012012080B1 (OSRAM) |
| CA (1) | CA2781467C (OSRAM) |
| CU (1) | CU20120080A7 (OSRAM) |
| DK (1) | DK3721904T3 (OSRAM) |
| ES (1) | ES2897500T3 (OSRAM) |
| IL (1) | IL219884A (OSRAM) |
| MX (1) | MX2012005863A (OSRAM) |
| MY (1) | MY165614A (OSRAM) |
| NZ (1) | NZ600096A (OSRAM) |
| PL (1) | PL3721904T3 (OSRAM) |
| PT (1) | PT3721904T (OSRAM) |
| RU (1) | RU2548772C2 (OSRAM) |
| WO (1) | WO2011061712A1 (OSRAM) |
| ZA (1) | ZA201204459B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| JP2011513479A (ja) | 2008-03-14 | 2011-04-28 | バイオコン・リミテッド | モノクローナル抗体、及びその（ｔｈｅｒｏｆ）方法 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR084939A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9, formas de dosificacion unitarias, articulo manufacturado, metodo |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA028278B1 (ru) | 2011-09-16 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9) |
| WO2013112438A1 (en) | 2012-01-23 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| EP2892550B1 (en) | 2012-09-07 | 2019-12-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| MX367034B (es) | 2012-11-06 | 2019-08-02 | Bayer Pharma AG | Formulacion para dominios de union biespecificos de celulas-t (bites). |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EP3024485B1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EA201690889A1 (ru) | 2013-11-12 | 2016-11-30 | Санофи Байотекнолоджи | Режимы дозирования для применения ингибиторов pcsk9 |
| US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
| KR20240017117A (ko) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN104922668B (zh) * | 2014-12-10 | 2019-08-23 | 信达生物制药(苏州)有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| KR20240172758A (ko) | 2015-08-18 | 2024-12-10 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| MA46334A (fr) * | 2016-09-27 | 2019-08-07 | Fresenius Kabi Deutschland Gmbh | Composition pharmaceutique liquide |
| ES2991182T3 (es) | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
| CN106800598B (zh) * | 2017-02-09 | 2020-08-07 | 广州桂雨生物科技有限公司 | 一种抗体保存液及其制备方法 |
| US20210023216A1 (en) * | 2018-03-23 | 2021-01-28 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| UA128098C2 (uk) | 2019-02-18 | 2024-04-03 | Елі Ліллі Енд Компані | Водна фармацевтична композиція антитіла проти il-17a |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| US11498626B2 (en) | 2020-11-11 | 2022-11-15 | Rivian Ip Holdings, Llc | Vehicle tailgate assembly |
| CN113289027B (zh) * | 2021-05-18 | 2022-07-01 | 中国兽医药品监察所 | 一种通用型单克隆抗体耐热保护剂 |
| WO2024083074A1 (en) * | 2022-10-17 | 2024-04-25 | Beigene, Ltd. | Formulations containing anti-tigit antibody and methods of use thereof |
| CN117214426A (zh) * | 2023-09-20 | 2023-12-12 | 暨南大学 | 一种用于免疫组织化学检测的抗体稀释液及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| NZ500539A (en) * | 1995-07-27 | 2001-11-30 | Genentech Inc | An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer |
| US5810597A (en) * | 1996-06-21 | 1998-09-22 | Robert H. Allen, Jr. | Touch activated audio sign |
| PT1314437E (pt) | 2000-08-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Preparações estabilizadas contendo anticorpo |
| WO2003009817A2 (en) * | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| RU2332986C2 (ru) * | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
| NZ597082A (en) * | 2005-10-13 | 2013-11-29 | Human Genome Sciences Inc | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases |
| WO2007147001A2 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| MX2009006199A (es) * | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Formulacion parenteral de anticuerpos abeta. |
| CN101199483B (zh) * | 2006-12-14 | 2011-01-26 | 上海中信国健药业股份有限公司 | 一种稳定的抗her2人源化抗体制剂 |
| EP2119453B1 (en) * | 2006-12-26 | 2015-05-20 | Centro de Inmunolgía Molecular | Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia |
| BRPI0806313A2 (pt) * | 2007-01-09 | 2011-09-06 | Wyeth Corp | Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| JP5513380B2 (ja) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合剤の組成物 |
| WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
-
2010
- 2010-11-19 EP EP20174783.9A patent/EP3721904B1/en active Active
- 2010-11-19 CA CA2781467A patent/CA2781467C/en active Active
- 2010-11-19 PT PT201747839T patent/PT3721904T/pt unknown
- 2010-11-19 CN CN201080060508.0A patent/CN102770157B/zh active Active
- 2010-11-19 PL PL20174783T patent/PL3721904T3/pl unknown
- 2010-11-19 MY MYPI2012002248A patent/MY165614A/en unknown
- 2010-11-19 JP JP2012539465A patent/JP5896471B2/ja active Active
- 2010-11-19 EP EP10831248.9A patent/EP2501408B1/en active Active
- 2010-11-19 US US13/510,929 patent/US20120231009A1/en not_active Abandoned
- 2010-11-19 BR BR112012012080-8A patent/BR112012012080B1/pt active IP Right Grant
- 2010-11-19 ES ES20174783T patent/ES2897500T3/es active Active
- 2010-11-19 WO PCT/IB2010/055296 patent/WO2011061712A1/en not_active Ceased
- 2010-11-19 AU AU2010320515A patent/AU2010320515B2/en active Active
- 2010-11-19 RU RU2012125254/15A patent/RU2548772C2/ru active
- 2010-11-19 NZ NZ600096A patent/NZ600096A/xx unknown
- 2010-11-19 DK DK20174783.9T patent/DK3721904T3/da active
- 2010-11-19 MX MX2012005863A patent/MX2012005863A/es active IP Right Grant
- 2010-11-19 KR KR1020127015910A patent/KR101333276B1/ko active Active
-
2012
- 2012-05-20 IL IL219884A patent/IL219884A/en active IP Right Grant
- 2012-05-21 CU CU2012000080A patent/CU20120080A7/es unknown
- 2012-06-18 ZA ZA2012/04459A patent/ZA201204459B/en unknown
-
2015
- 2015-12-28 JP JP2015256586A patent/JP2016104780A/ja active Pending
-
2018
- 2018-11-20 US US16/197,228 patent/US20190321285A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,316 patent/US20210290525A1/en not_active Abandoned
-
2023
- 2023-05-19 US US18/199,675 patent/US20240058263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20120080A7 (es) | Formulaciones de anticuerpo | |
| CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| CR11005A (es) | Formulaciones estables de anticuerpos | |
| AR079556A1 (es) | Formacion de anticuerpos | |
| CO6751287A2 (es) | Composición antigénetica de micobacteria | |
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| PE20141175A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| BRPI0915076A2 (pt) | composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas. | |
| WO2011103490A3 (en) | INTEGRIN αVβ8 NEUTRALIZING ANTIBODY | |
| BRPI1013780A2 (pt) | composições para imunização contra staphylococcus aureus. | |
| AR061348A1 (es) | Preparados estables de laquinimod | |
| AR061400A1 (es) | Agentes para suprimir el dano a los islotes transplantados despues del transplante de islotes | |
| CL2012002695A1 (es) | Articulo para fumar, que comprende una primera parte que contiene una fuente de material para fumar y una segunda parte que tiene al menos un extremo que esta configurado para desplazarse en relacion con la primera parte, en donde el articulo ademas comprende un agente modificador de humo que se libera en el articulo para fumar; y envase. | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| EP2507381A4 (en) | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS | |
| CL2012003657A1 (es) | Formulacion estable que comprende la proteina iduronato -2- sulfatasa y un tensoactivo de polisorbato; contenedor que comprende dicha formulacion; uso de dicha formulacion para tratar sindrome de hunters. | |
| ECSP10010588A (es) | Formulacion de medicamento solida con liberacion retardada | |
| CL2013000098A1 (es) | Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. | |
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE | |
| WO2011028961A3 (en) | Anti-botulism antibody coformulations | |
| ECSP13013093A (es) | Composiciones líquidas de limpieza de sal | |
| BR112014003139A2 (pt) | musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso | |
| WO2012006367A3 (en) | Compositions and methods for treating influenza | |
| WO2010053610A3 (en) | Stable anthrax vaccine formulations |